Jakarta, June 12, 2025 – Etana Biotechnologies Indonesia (Etana) has officially entered into a partnership with the Faculty of Military Pharmacy of University of Defense (Unhan) to strengthen collaboration in education, research, and community service.
Read MoreJakarta, May 19, 2025 – PT Etana Biotechnologies Indonesia (Etana) confirmed its dedication to helping Indonesia become self-sufficient in pharmaceuticals by getting approval for Clinical Trials (PPUK) and a Marketing Authorization Number (NIE) from the Indonesian Food and Drug Authority (BPOM RI) for two important products.
Read MoreJakarta, April 12, 2025 - PT Etana Biotechnologies Indonesia (Etana) introduced two new products in collaboration with global partner BeiGene (tislelizumab) and BRUKINSA® (zanubrutinib) during the Etana Oncology Summit, which also served as a scientific forum to discuss the latest advancements in cancer therapies.
Read MoreJakarta, March 14, 2025 – In commemoration of World Kidney Day, Etana Biotechnologies Indonesia (Etana) reaffirms its commitment to supporting innovation in kidney disease treatment in Indonesia. As a biotechnology company, Etana actively contributes to providing high-quality and affordable medicines for patients, especially those suffering from kidney disease.
Read MoreJakarta, December 10, 2024 – PT Etana Biotechnologies Indonesia (Etana), an Indonesian biopharmaceutical company, has obtained marketing authorization for two innovative cancer therapies, Tislelizumab (ETAPIDI®) and Zanubrutinib (BRUKINSA®). Developed by BeiGene, which plans to change its name to BeOne Medicines, a global oncology leader committed to making cutting-edge and accessible treatments available worldwide, these therapies are set to transform cancer care in Indonesia by combining global advancements with local accessibility.
Read MoreJakarta, 14 November 2024 – PT Etana Biotechnologies Indonesia (Etana), a local Indonesian biopharmaceutical company and Celltrion, a leading global biopharmaceutical company specialized in researching, developing and manufacturing innovative therapeutics medicine, today announced that the companies have entered a strategic distribution and marketing agreement for Herzuma® (trastuzumab) and Truxima® (rituximab). These two treatments are first-line targeted therapies for breast cancer and non-Hodgkin's lymphoma, and listed in the National Formulary (Fornas) and e-catalogue.
Read More
